Home Newsfeeds Mizuho Maintains Buy on Humana, Raises Price Target to $615

Mizuho Maintains Buy on Humana, Raises Price Target to $615

Mizuho analyst Ann Hynes maintains Humana (NYSE:HUM) with a Buy and raises the price target from $529 to $615.

byBenzinga Newsdesk

November 10, 2022

1 minute read

Mizuho analyst Ann Hynes maintains Humana (NYSE:HUM) with a Buy and raises the price target from $529 to $615.

Inventiva Announces The Screening Of The First Patient In LEGEND, A Phase IIa Combination Trial With Lanifibranor And Empagliflozin In Patients With NASH And T2D

By Benzinga Newsdesk

July 7, 4:01 PM

The Phase IIa Proof-of-Concept study is designed to assess the safety and efficacy of lanifibranor in combination with the SGLT2 inhibitor empagliflozin for the treatment of patients with non-cirrhotic non-alcoholic

IVA

Chicken Soup For The Soul Entertainment Signs Global Agreement With Entertainment And Social Platform TaTaTu For Ad-Supported Video-On-Demand Content

By Happy Mohamed

May 15, 4:27 PM

TaTaTu will launch in new international markets using movies and television series owned by Chicken Soup for the Soul Entertainment TaTaTu is the first social media platform to reward users for viewing content and

CSSE

Leafly Shifts Focus From Cannabis News To Product And Marketplace-Driven Content

By Joana Scopel

March 29, 2:21 PM

Leafly Holdings Inc. (NASDAQ: LFLY), a leading online cannabis marketplace and resource for marijuana users, is shifting its focus from journalism about the industry to offering consumer-oriented content, which will include product information.

LFLY

Stock Market’s ‘Once-In-A-Generation’ Opportunity Is Near, Says Bernstein Analyst: ‘You Are Going To See A Bear Market’

By Benzinga Neuro

January 21, 10:45 PM

RBA has been warning about a once-in-a-generation opportunity for several months, and now, it seems to be on the horizon.

AAPL

Mizuho Maintains Buy on Humana, Raises Price Target to $615

Related Posts

Inventiva Announces The Screening Of The First Patient In LEGEND, A Phase IIa Combination Trial With Lanifibranor And Empagliflozin In Patients With NASH And T2D

Chicken Soup For The Soul Entertainment Signs Global Agreement With Entertainment And Social Platform TaTaTu For Ad-Supported Video-On-Demand Content

Leafly Shifts Focus From Cannabis News To Product And Marketplace-Driven Content

Stock Market’s ‘Once-In-A-Generation’ Opportunity Is Near, Says Bernstein Analyst: ‘You Are Going To See A Bear Market’